The management had recently expressed confidence about the progress of the trials, and the results will be announced shortly. The stock moved up on slightly better volumes. The company had recently announced that it will make presentations on SNS01T for blood-borne cancer care at the American Society of Hematology (ASH) Annual Meeting which is going to be held early next month. It will present a poster to provide an update on the current results of the trials, and it will also make an oral presentation of new results with SNS01T in non-clinical studies. The results in previous stages were good, and hopefully the results of this phase will also be good on tolerability and efficacy. The preclinical trials on mice, and the cohort 1 & 2 trials results were good both on safety / tolerability and efficacy. The primary purpose of the trials so far has been to test the safety and tolerability. In addition, the trials explore whether SNS01T is an effective treatment for multiple myeloma, mantle cell lymphoma and diffuse large B cell lymphoma. The cohort 3 & 4 trials involve much higher doses so safety / tolerability will be relatively more important. The efficacy is also likely to be better. The company has made efforts to speed up the trials by expansion of centers etc. so that the research can progress faster. Since the culmination of the trial may take some time, Senesco will require to raise more funds from time to time. As per the latest 10Q, Cash & equivalents are sufficient for the operations till March 2014, and it plans to get more funds for its future R&D and commercialization activities by execution of new licensing agreements, and through equity and debt funding. Funding will become easier if the results of the trials continue to show promise.
